Vanguard Group Inc Processa Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.18 - $0.84 $19,758 - $92,208	-109,772 Reduced 31.87%	234,653 $79,000
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.53 $4,140 - $9,144	-17,254 Reduced 4.77%	344,425 $86,000
Q1 2023 May 15, 2023	SELL	$0.41 - $1.3 $4,980 - $15,792	-12,148 Reduced 3.25%	361,679 $180,000
Q4 2022 Feb 10, 2023	BUY	$1.1 - $50.0 $141 - $6,450	129 Added 0.03%	373,827 $411,000
Q3 2022 Nov 14, 2022	BUY	$2.0 - $46.8 $200 - $4,680	100 Added 0.03%	373,698 $845,000
Q4 2021 Feb 14, 2022	SELL	$4.03 - $8.42 $1,180 - $2,467	-293 Reduced 0.08%	373,598 $1.83 Million
Q3 2021 Nov 12, 2021	BUY	$5.28 - $8.61 $3,801 - $6,199	720 Added 0.19%	373,891 $3.2 Million
Q2 2021 Aug 13, 2021	BUY	$6.15 - $10.95 $2.3 Million - $4.09 Million	373,171 New	373,171 $3.06 Million

Ticker PCSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,856,200
Market Cap $18.4M
Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosi...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.